[ Price : $8.95]
FDA approves updated labeling on Pfizers s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with metastati...[ Price : $8.95]
Roche moves prasinezumab into a Phase 3 trial after two mid‑stage trials and their open‑label extensions hinted at a d...[ Price : $8.95]
Milestone Pharmaceuticals submits its response to a March-issued FDA complete response letter on the companys NDA for irregular he...[ Price : $8.95]
Zyno Medical recalls certain Z-800 infusion pumps because they were released to customers with incorrect software versions.[ Price : $8.95]
Qalitex Laboratories issues an alert to dietary supplement and wellness product sellers on Amazon about a growing overlap between ...[ Price : $8.95]
An AbbVie Phase 3 (VERONA) clinical trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk my...[ Price : $8.95]
Incyte reports the first positive clinical data from studies evaluating a novel, first-in-class targeted monoclonal antibody in pa...[ Price : $8.95]
FDA grants Sumitomo Pharma a fast-track designation for nuvisertib (TP-3654) for treating patients with intermediate or high-risk ...